Activities

Altered cellular signalling and immune dysregulation are hallmarks of most auto-immune, inflammatory and chronic viral diseases. The expression, signalling and activity of chemokines and IFN are often altered in these pathologies but the molecular mechanisms and fine regulation at play are not completely understood. Most viruses have evolved strategies to hijack, bypass or lure these signal transducers and cellular effectors to favour their replication and/or to corrupt or evade immunity.

Our research interests revolve around two axes:

  • Fundamental research aiming at gaining new insights into the complex structural and cellular mechanisms that lead to altered cellular signalling and cell transformation.
  • Translational research aiming at developing novel tools and therapeutic approaches to interfere or modulate these processes and viral replication.

Research projects

  • Studying the structure and function of human chemokine receptors CXCR4, CXCR7 and CXCR3 and viral receptors and deciphering homeostatic and pathogenic molecular interactions, signalling and intracellular trafficking induced by their endogenous and viral ligands.
  • Designing novel chemokine-receptor inhibitors interfering with chemokine receptor signalling as well as with HIV entry and developing viral tools for applied research and for determining viral tropism as well as resistance to entry inhibitors.
  • Studying the molecular mechanisms of HIV assembly and viral protein trafficking, paying particular care to the impact of subtype-related variability.
  • Investigating the molecular mechanisms leading from chronic inflammation to cancer development in chronic viral infections, focusing on the role of the Interferon-induced proteins APOBEC3 and SAMHD1 in cellular DNA damage, viral integration of DNA viruses and cellular homeostasis.

Featured Publications

Atypical opioid receptors: unconventional biology and therapeutic opportunities.

  • Immuno-Pharmacology and Interactomics
October 05, 2021
2021 Oct. Pharmacol Ther.108014. Online ahead of print.
By:
  • Palmer CB
  • Meyrath M
  • Canals M
  • Kostenis E
  • Chevigne A
  • Szpakowska M.

Maraviroc prevents HCC development by suppressing macrophages and the liver progenitor cell response in a murine chronic liver disease model.

  • Immuno-Pharmacology and Interactomics
September 30, 2021
2021 Sep. Cancers.13(19):4935.
By:
  • Passman AM
  • Strauss RP
  • McSpadden SB
  • Finch-Edmondson M
  • Andrewartha N
  • Woo KH
  • Diepeveen LA
  • Zhao W
  • Fernandez-Irigoyen J
  • Santamaria E
  • Medina-Ruiz L
  • Szpakowska M
  • Chevigne A
  • Park H
  • Carlessi R
  • Tirnitz-Parker JEE
  • Blanco JR
  • London R
  • Callus BA
  • Elsegood CL
  • Baker MV
  • Martinez A
  • Yeoh GCT
  • Ochoa-Callejero L.
See all publications

Contacts

Andy Chevigne

Ph.D., ADR

29, rue Henri Koch
L-4354Esch-sur-Alzette
Luxembourg
Tel. : +352 26970-336